Ischemic heart disease is the leading cause of morbidity and mortality in the western world. Ischemic damage can occur by acute myocardial infarction, stable angina, cardiac stunning, and myocardial hibernation. In addition, Fscheduled_ ischemic events, occurring during cardiac surgery, heart transplantation, and elective angioplasty, can also result in cardiac damage. Ischemic or pharmacological preconditioning can decrease the extent of damage to the myocardium. Although the mechanism of preconditioning-mediated cardioprotection is not fully understood, (PKC has been implicated as a critical mediator of this process in animal studies. The use of isozyme-specific pharmacological tools has permitted a better elucidation of the upstream stimuli and the downstream transducers of (PKC in the pathways leading to cardioprotection. While little is known about the role of (PKC in these pathways in humans, animal studies suggest a potential therapeutic role of (PKC. This review will focus on the role of (PKC in cardiac protection and on the signal transduction cascades that have been implicated in this protection.
Introduction
Ischemic heart disease is the leading cause of death in the western world and the ability to reduce this damage by subjecting the heart to short bouts of ischemia prior to the prolonged ischemic episode, a process termed ischemic preconditioning, has been a focus of research since its first description [1] . Preconditioning reduces damage to the myocardium when the time of cardiac ischemia is predictable, such as the damage occurring during bypass surgery, cardiac transplantation, and elective angioplasty. The elucidation of signaling molecules that mediate ischemic/hypoxic preconditioning allowed for the identification of pharmacological agents that can act as preconditioning mimetics. Here, we will review the role of epsilon protein kinase C ((PKC) in the molecular events leading to preconditioning. We will also describe pharmacological preconditioning mimetics and the potential of PKC regulating drugs as therapeutic agents in a clinically relevant setting.
PKC isozymes in ischemic/hypoxic preconditioning
Over 10 years ago, Ytrehus et al., showed that inhibition of PKC blocks the protection afforded by ischemic/hypoxic preconditioning in a rabbit model [2] . However, which isozyme mediates this effect is still controversial (Table 1) . Whereas (PKC and DPKC translocate from the cytosolic fraction to the particulate fraction in ischemic/hypoxic preconditioned rabbit myocardium [3] , yPKC and (PKC translocate in ischemic/hypoxic preconditioned neonatal rat cultured cardiomyocytes and in isolated rat hearts [4, 5] .
Cardiac-specific overexpression of (PKC or expression of a (PKC-activating peptide confers cardioprotection against ischemia/reperfusion-mediated damage [6, 7] , and ischemic/hypoxic preconditioning fails to diminish infarct size in (PKC knockout mice [8] . Therefore, (PKC is required and sufficient to induce cardioprotection. Cardiac specific expression of a yPKC-activating peptide increases ischemia/reperfusion mediated damage [9] and expression of a yPKC-inhibitory peptide decreases it [10, 11] . In contrast, some studies suggest that yPKC has a cardioprotective role in ischemic/hypoxic preconditioning [12 -14] and that yPKC knockout mice exhibit increased damage following ischemic preconditioning (Table 1) [12] .
The use of transgenic or knockout mice was instrumental in identifying the role of specific PKC isozymes during ischemia/reperfusion. However, the challenge in relying on genetically modified mice is that sustained gain or loss of a PKC function may alter cardiac development and functions not related to the response to the acute ischemic event. A better approach is the use of pharmacological tools to study the roles of PKC isozymes in ischemic/hypoxic preconditioning. These could then be applied clinically as therapeutic agents for ischemic heart disease.
Pharmacological tools to study the role of PKC in cardiac ischemia
PKC activators, such as phorbol 12-myristate 13-acetate (PMA) and diacylglycerol (DAG), or various PKC inhibitors have been used to study the roles of PKC during ischemia/reperfusion. However, these agents show poor selectivity for individual PKC isozymes [15 -18] . Because of the opposing roles of many of the individual isozymes in the cardiac response to ischemia/reperfusion injury [9, 19, 20] , these non-selective pharmacological tools may have contributed to the conflicting data [21] .
To generate isozyme-selective pharmacological tools, we have focused on the observation that when activated, PKC isozymes translocate from one cellular compartment to another, placing the activated PKCs near their corresponding substrates. We showed that the location of the activated PKC isozymes is determined, in part, by their binding to selective anchoring proteins, termed Receptors for Activated C Kinases (RACKs) [22] . We have capitalized on this observation and have rationally designed PKC isozyme-selective regulating peptides [23] that modulate the subcellular location of PKCs [22, 23] . Peptide inhibitors compete with the binding of an isozyme to its RACK, whereas peptide activators promote this interaction. The peptides (6-10 amino acids in length) are highly selective and effective (IC 50 at 1-10nM) [23] , and membrane permeable due to conjugation with carrier peptides such as TAT 47 -57 [24] . Use of these isozyme-selective PKC regulators in several laboratories has helped in determining the role of PKC isozymes both in vitro and in vivo.
The use of the (PKC-selective peptide activator, c(RACK, prior to or early during the ischemic event, conferred cardioprotection against ischemia/reperfusion injury, whereas the (PKC-selective peptide inhibitor, (V1-2, prevented ischemic/hypoxic or pharmacologic preconditioning in mice, rats, rabbits and pigs [4, 7, 9, 19, 25, 26] . Infusion of the yPKC-selective peptide inhibitor, yV1-1, during reperfusion confers cardioprotection against reperfusion injury but exerts no effect when delivered just prior to ischemia [11, 27] .
Although treatment with a yPKC-selective peptide activator, cyRACK immediately before ischemia exagger- yPKC-inhibitory peptide Rat, Pig Inhibits yPKC Decreases [11, 27] yPKC-activating peptide Mouse Activates y and subsequently-(PKC ated cardiac damage, yPKC activation an hour prior to the ischemic event resulted in cardioprotection in the mouse heart [9, 28] . The protection afforded by yPKC activation was inhibited by both an A1 receptor antagonist, DPCPX, and by the (PKC inhibitor (V1-2, suggesting that yPKCmediated cardioprotection is dependent upon both (PKC and adenosine-mediated pathways [28] . The role of yPKCinduced adenosine-dependent cardioprotection was also suggested in early studies in myocytes where yPKC was overexpressed [14] . PKC activation increases 5V -nucleotidase activity, which then dephosphorylates 5V -AMP to form adenosine [29, 30] . Adenosine transporter function is also regulated by y and/or (PKC [31, 32] . Non-selective PKC regulators suggest that yPKC may also be protective in opiate-induced cardioprotection [33] . Therefore, (PKC activation is required for preconditioning and activation of yPKC during reperfusion is detrimental whereas transient activation of yPKC early prior to ischemia may induce cardioprotection by (PKC activation (Fig. 1 ).
The signal transduction pathways of EPKC in cardiac preconditioning
Both rational search and the systematic proteomic studies identifying proteins that are complexed with (PKC assisted in elucidating the pathway of (PKC in cardiac preconditioning [34 -41] . In the following sections, some of the upstream stimuli and downstream transducers of (PKC, as well as end-effectors of preconditioning will be discussed.
Upstream stimuli of ePKC
Most of the preconditioning mimetic agents activate (PKC through G protein-coupled heptahelical transmembrane receptors (GPCR). Ligands of the GPCR are released during a brief ischemic event (including adenosine, catecholamines, angiotensin II, bradykinin, and endothelin) and induce preconditioning through activation of the corresponding G proteins [5,42 -46] . The active G proteins then stimulate phospholipases to generate diacylglycerol and in some cases inositol trisphosphate, which releases calcium from internal stores. Diacylglycerol (with or without calcium) then activates PKC ( Fig. 1 ) [47] . As discussed later, it is possible that reactive oxygen species and/or nitric oxide, which are both generated during the brief ischemic event, can cause direct modification of (PKC leading to its activation [96, 100] .
Downstream transducers of ePKC: ERKs and Lck in ischemic/hypoxic preconditioning
Ischemic/hypoxic preconditioning result in the phosphorylation and activation of p42 and p44 extracellular signal- Fig. 1 . Proposed mechanism of (PKC-mediated cardioprotection. Generation of mitochondrial ROS during intermittent reperfusion associated with ischemic preconditioning may lead to the activation of yPKC through ROS-dependent mechanisms either directly or indirectly. This increases adenosine generation and release. Adenosine binding to the heptahelical G protein-coupled receptors (A1/A3) activates phospholipase C by G-proteins (Gi/o). Generation of diacylglycerol and inositol-triphosphate results in calcium release and activation of (PKC. Cardioprotection is afforded by activation of the extracellular signalregulated kinases (p44/p42) and through translocation of the activated~PKC to and opening of mitochondrial K ATP channels, thereby decreasing ROS generation and calcium overload. regulated kinases (ERKs) and the ERK inhibitor, PD98059, attenuates the cardioprotection afforded by ischemic/hypoxic preconditioning [48, 49] . Administration of the (PKC activator, c(RACK, which reduces infarct size and creatine phosphokinase release in isolated perfused mouse hearts, also resulted in ERKs phosphorylation [26, 28] . Finally, (PKC co-immunoprecipitates with and phosphorylated ERKs at the mitochondria, where the (PKC-ERKs complex can phosphorylate the pro-apoptotic protein BAD [37] . Therefore, the phosphorylation of ERKs by (PKC during ischemic/hypoxic preconditioning may confer cardioprotection by inhibition of pro-apoptotic proteins (Fig. 1 ) [28, 37, 50] .
Another downstream transducer of (PKC is a member of the Src family of tyrosine kinases, Lck. Preconditioning induces a signaling complex with (PKC resulting in phosphorylation and activation of Lck in cardiac cells [6] . Disruption of the complex by ablation of the Lck gene, abrogated the infarct-sparing effects of preconditioning or (PKC overexpression, indicating that the formation of (PKC-Lck signaling modules is required for the manifestation of a cardioprotective phenotype [6] .
4.3. Effectors of preconditioning: K ATP channels, mitochondrial permeability transition pore and ePKC in ischemic/ hypoxic preconditioning (PKC translocates from the cytosol to the sarcolemmal membrane and to mitochondria upon activation [33, 51] . The ATP-sensitive K + channel (K ATP channel) exists both in the sarcolemmal membrane and in the mitochondria, and is likely an end-effector of ischemic/hypoxic preconditioning [52] . The K ATP channel is inhibited by high levels of adenosine triphosphate (ATP) and opens as ATP levels fall [53] . Other studies suggest that the surface or sarcolemmal K ATP channel might be one of the critical effectors of the cardioprotective effects of ischemic/hypoxic preconditioning [54] . Opening of the sarcolemmal K ATP channel by hypoxia or pharmacological K ATP channel openers may increase cell viability by shortening cardiac action potential duration, thereby reducing calcium overload during ischemia and early reperfusion [55, 56] . PKC can directly activate single sarcolemmal K ATP channels at physiological levels of ATP in rabbit ventricular myocytes [57] . Stimulation of PKC by PMA activates the sarcolemmal K ATP channel and mimics the cardioprotective effect of ischemic preconditioning. These studies also showed that glibenclamide or 5-hydroxydecanoate (K ATP channel blockers) inhibits the PMA-induced preconditioning in chick embryo ventricular myocytes [58] .
Garlid et al. demonstrated that a potent opener of mitochondrial K ATP , diazoxide, has little effect on cardiac action potential duration, but it decreases cardiac damage from ischemia in isolated perfused rat hearts [59] , an effect blocked with the mitochondrial K ATP channel blocker 5-hydroxydecanoate (5-HD) . Therefore, the mitochondrial K ATP channel is a likely end-effector in preconditioningmediated cardioprotection. Opening of the mitochondrial K ATP channel stabilized the mitochondrial membrane potential, reduces mitochondrial Ca 2+ overload, prevents ATP depletion and the generation of reactive oxygen species [60, 61] . The PKC activator phorbol ester was found to increase the mitochondrial K ATP channel activity [62] , and infarct size limitation by a selective mitochondrial K ATP channel opener (diazoxide) was abolished by a selective inhibitor of the mitochondrial K ATP channel 5-HD but not by a PKC inhibitor (calphostin C) [63] . These data indicate that the mitochondrial K ATP channel is an end-effector of preconditioning and that possibly (PKC is upstream of this.
The mitochondrial permeability transition pore (MPTP) is downstream of (PKC [64, 65] , and is another candidate effector of preconditioning [65 -67] . Opening of the MPTP allows water and solutes to enter the mitochondria, increasing matrix volume, and rupturing the outer mitochondrial membrane. This can lead to the release of intermembrane cytochrome c, which in turn can trigger apoptosis. In addition, pore opening uncouples mitochondria, leading to ATP hydrolysis and collapse of the mitochondrial membrane potential. The MPTP is closed during ischemia and only opens in the first few minutes of reperfusion [68] . Baines et al. demonstrated that (PKC interacts with MPTP, leading to phosphorylation of MPTP associated voltage-dependent anion channel [64] . Additionally, incubation of isolated cardiac mitochondria with recombinant (PKC inhibits Ca 2+ -induced mitochondrial swelling, a correlate of MPTP opening [64] . Overexpressed (PKC interacts with the MPTP components and inhibits Ca 2+ -induced MPTP opening [64] , and the MPTP opener atractyloside significantly attenuated this infarct-sparing effect of (PKC overexpression [64] . Therefore, the cardioprotective effects of (PKC may partly or solely be due to the enzyme's ability to interact with and maintain the MPTP in a closed conformation.
ePKC pathway in late preconditioning
Activation of (PKC also mediates the protective effects of late preconditioning. This is a delayed protective adaptation, whereby preconditioning stimuli enhance the resistance of the heart to ischemia/reperfusion injury 12 -72 h later [69] . Late preconditioning results from upregulation of several cardioprotective genes, including inducible nitric oxide synthase, cyclooxygenase-2, heme oxygenase-1, aldose reductase and Mn superoxide dismutase, by activation of transcription factors, such as nuclear factor-kB (NFkB) and activator protein (AP)-1 [69,71 -73] .
PKC activates the I|B kinase that phosphorylates InB, an inhibitor of the transcription factor NF|B. Phosphorylated InB dissociates from NFnB, allowing its entry into the nucleus to exert transcriptional activity [71, 72] . Finally, (PKC has also been shown to translocate to the nucleus suggesting a possible role in the mediation of transcription there [5, 51] . Li et al. showed that activation of (PKC increased the DNA-binding activity of NFnB and AP-1 in adult rabbit cardiomyocytes, and this effect is completely abolished by inhibition of ERK with PD98059 [73] . Additionally, Xuan et al. showed that late preconditioning causes STAT1 and STAT3 phosphorylation by the (PKC-ERK pathway, resulting in the upregulation of COX-2 [74] . These data indicate that the (PKC-ERKs complex or (PKC alone activates transcription factors, leading to the upregulation of cardioprotective genes in late preconditioning.
ROS, PKC and preconditioning-mediated cardioprotection
There is a correlation between the generation of reactive oxygen species (ROS) and cardiac protection [75 -78] . Exogenous ROS mimic preconditioning whereas inclusion of anti-oxidants during preconditioning blocks cardioprotection [76, 79, 80] . Furthermore, pharmacological preconditioning with agents such as angiotensin II [77, 81] and K ATP channel openers [79,82 -85] increase the cardioprotective ROS production. What is the source of ROS? Mitochondrial respiratory chain inhibitors suggest that ROS such as superoxide generated by the mitochondria are important in cardioprotection (Fig. 1, [79,85] ). In contrast, the protective effects of ischemic/hypoxic preconditioning is lost in NADPH oxidase subunit, NOX-2, knock-out hearts suggesting that this enzyme is also a source of ROS [86] . Per Kimura et al., this can be reconciled if protection is first mediated by a mitochondrial source of ROS, which is subsequently enhanced through NADPH oxidase activation by JNK and p38 [81] .
The protective effect of ROS during preconditioning does not contradict the role of ROS during prolonged reperfusion in mediating cellular damage and death [87] . Real-time measurement of superoxide production in guinea pig hearts showed that ischemic/hypoxic preconditioning decreases superoxide production during both ischemia and reperfusion [88] . In addition, small amounts of superoxide are produced during the ischemic/hypoxic preconditioning stimulus [76, 78, 80] . Baines et al. showed that whereas the initial preconditioning stimulus affords protection through the generation of ROS, subsequent preconditioning stimuli may protect through other mechanisms involving adenosine [76] . Therefore, a small burst of ROS during the ischemic/ hypoxic preconditioning stimulus may mediate a decrease in ROS production during reperfusion and/or may sensitize the cell to the burst of ROS by increasing antioxidant defenses; data exist to support these scenarios [78, 88, 89] .
Work by Bolli et al . demonstrated that nitric oxide (NO) generation during ischemic preconditioning may act as a trigger of preconditioning-mediated cardioprotection [90, 91] . Additionally, NO donors afforded the same protection seen during ischemic/hypoxic preconditioning. Inclusion of peroxynitrate and hydroxyl radical scavengers completely abrogated the effects of the NO donors, suggesting that the NO-mediated mechanism of protection involves the generation of pro-oxidant species [92] . Together these data suggest that whereas elevated levels of ROS can be deleterious to the cell, small amounts of ROS may be protective by triggering cardiac preconditioning.
What is the relationship between yPKC and ROS generation? Ischemic/hypoxic preconditioning in a yPKC knockout heart resulted in diminished ROS production and decreased cardiac protection, placing yPKC upstream in the cascade leading to ROS generation [12] . Furthermore, yPKC translocation to the mitochondria increases ROS production and selective inhibition of this translocation reduces ROS levels and improves mitochondrial function [93] . yPKC is also activated by ROS [94] . Specifically, exposure of cells to hydrogen peroxide and ultraviolet radiation (a ROS generator) results in tyrosine phosphorylation and activation of this isozyme [95, 96] as well as translocation of yPKC to the mitochondria [97, 98] . Therefore, yPKC may be both upstream and downstream of ROS generation (Fig. 1) .
In addition to the ROS-mediated activation of yPKC, recent studies delineate the involvement of ROS in the activation of (PKC. Removal of hydrogen peroxide during ischemic/hypoxic preconditioning of chick cardiomyocytes resulted in the abrogation of (PKC activation [99] . Additionally, treatment of these cells with hydrogen peroxide activates (PKC and induces cardioprotection from hypoxia/reoxygenation injury, which is blocked by inhibition of K ATP channel opening [99] .
In addition to the activation of (PKC by hydrogen peroxide, treatment with NO selectively activates (PKC in the rabbit heart, leading to late preconditioning-like effects [100] . Ischemia-induced generation of NO is also sufficient to activate (PKC [100] and association with Src, which when blocked, can abolish NO-induced late preconditioning [39] . These data suggest that oxidant-mediated activation of (PKC may play a role in cardioprotection. Conversely, (PKC may also inhibit ROS production by preserving cellular ATP levels: preconditioning places this isozyme at the mitochondrial pore, leading to protection of mitochondrial function, which should decrease ROS generation as well as maintain ATP levels ( Fig. 1) [64,101 ].
Anesthetic-mediated cardioprotection
Because preconditioning is particularly applicable to cardiac protection from scheduled ischemia, such as that occurring during surgeries, the possible preconditioningmimetic effect of some general anesthetics is important to review. Halogenated volatile anesthetics mimic preconditioning in a mechanism that may depend on (PKC activation [102, 103] . For example, inhibition of (PKC with (V1-2 inhibits isoflurane-induced protection of human myocardium [104] . In addition to halogenated volatile anesthetics, the noble gas xenon induces translocation of (PKC and pharmacological preconditioning in rat hearts, in vivo. This effect is blocked by a non-selective PKC inhibitor, calphostin C [105] . In another model of isoflurane-induced preconditioning, yPKC is activated by ROS in a K ATP channel-independent mechanism, and preconditioning by isoflurane sensitizes the sarcolemmal K ATP channel that is blocked in the presence of the yPKC-specific inhibitor, yV1-1 [106] . Finally, opioids (analgesics that are often used in conjunction with general anesthetics) also mimic preconditioning, and require activation and translocation of yPKC to the mitochondria [13, 48] . Together these data suggest that in addition to (PKC-mediated protection by some general anesthetics, there is a possible role of yPKC in anesthetic preconditioning that is downstream of ROS generation.
A few clinical studies of anesthetic preconditioning on a small number of patients have been conducted, with somewhat limited success. Five-minute exposure to isoflurane before aortic cross-clamping and cardioplegic arrest reduced cardiac damage assessed by the release of troponin I and creatine kinase-MB [107] . Sevoflurane and desflurane preserved left ventricular function after coronary bypass surgery in patients with three-vessel disease and an ejection fraction below 50% [108] . However, no clinical investigation to date has shown decreased long-term morbidity and mortality by anesthetic preconditioning nor the role of PKC isozymes in this process.
PKC and cardiac transplant
Although 1-year allograft survival and patient survival after cardiac transplantation continues to improve, the incidence of heart failure caused by graft coronary artery disease has not changed [109] . Ischemia/reperfusion injury is the strongest alloantigen-independent factor for the subsequent development of this graft coronary disease [110] . Furthermore, transplant ischemia induces a proinflammatory environment, which includes an influx of injurious cytokines and chemokines and upregulation of adhesion molecules on the vascular endothelium [111] .
The potential benefit of PKC regulation and preconditioning mimetics around the time of transplantation was recently examined in two rodent models of cardiac transplantation. Donor hearts were harvested into solution containing the (PKC activator, c(RACK, as a preconditioning agent, and the recipient animals were intraperitoneally treated once with the yPKC inhibitor, yV1-1, before reperfusion, to prevent reperfusion injury in genetically mismatched transplantation of hearts in mice [112] and in rats [113] . Although the animals were treated with the immunosuppressive drug, cyclosporine, acute treatment with these PKC regulators reduced immediate pro-inflammatory responses. Importantly, graft coronary artery disease was inhibited by more than 50% and improved cardiac allograft function was also noted by 30 and 90 days post-transplantation [112, 113] . Therefore, pharmacological preconditioning including an (PKC activator with or without treatment with yPKC inhibitor may be beneficial in improving patient survival after cardiac transplantation surgery.
Potential clinical implications
The seminal discovery of preconditioning over 20 years ago stirred extensive studies to elucidate the molecular basis of this phenomenon, mainly because of its potential to ameliorate human health. The therapeutic intervention by pharmacological preconditioning may be possible in situations when the timing of ischemia is predetermined, such as during cardiac surgery with extracorporeal circulation or, as discussed above, just prior to cardiac transplant surgery. Further, patients at high risk for eminent infarction may also benefit from preconditioned mimetics. Based on data generated in several independent laboratories using five animal models (mice, rats, rabbits and pigs) and human tissue [4, 7, 9, 11, 25, 26, 112, 113] , it appears that selective activation of (PKC provides such protection against ischemic damage. These studies also indicate that (PKC activation is an early step in this pathway. Furthermore, the finding that treatment with c(RACK during ischemia also reduced the incidence of malignant ventricular arrhythmia in an in vivo model of acute myocardial infarction [26] suggest an additional benefit for this treatment. Although the sustained treatment with c(RACK is well tolerated and did not result in desensitization to the cardioprotective effect in animals [26, 114] , it remains to be determined whether activation of (PKC is well tolerated in humans having other co-morbidity factors including age, diabetes and obesity.
